Mesoporous Materials as Efficient Platforms for the Delivery of Bioactive Agents

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (10 November 2022) | Viewed by 2694

Special Issue Editors

1. Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, 1-7 Gh. Polizu St., 011061 Bucharest, Romania
2. Academy of Romanian Scientists, 54 Splaiul Independenței St., Bucharest, Romania
Interests: bio(nano)materials; synthesis methods; materials processing and design; advanced coatings; tissue engineering; drug delivery; characterization methods
Special Issues, Collections and Topics in MDPI journals
Department of Inorganic Chemistry, Physical Chemistry and Electrochemistry, Faculty of Applied Chemistry and Materials Science, University POLITEHNICA of Bucharest, 060042 Bucharest, Romania
Interests: nanomaterials and nanotechnologies; inorganic chemistry; drug delivery system; materials

Special Issue Information

Dear Colleagues,

Porous materials can be efficient carriers for a wide range of bioactive agents, especially used in medical applications because of the tunability of the size, surface, and morphology, and thus, can assure a proper delivery profile tuned according to the needs of the patients. Thus, the current Special Issue will be focused on the design and preparation of different mesoporous materials with predefined pore characteristics and specific surface. Pre- and post-synthesis surface functionalisation will be considered in order to determine a specific hydrophilic:hydrophobic ratio as well as to assure a proper interaction with the bioactive agents which are loaded and further controlled delivered. These systems will be used in the treatment of cancer, infections, osteoporosis, etc., as major concerns of our century, but also in a hot topic related to the microbiota associated diseases, it being well known that dysbiosis can lead to severe imbalances and even severe diseases of different natures: cardiovascular, immunity, cancers, obesity, etc. Within this Special Issue, we are looking for short communications, original papers, and review papers dealing with mesoporous materials as platforms in drug delivery for the treatment of different diseases, including those related to dysbiosis.

The main potential subtopics include, but are not limited to:

  • Design and production of mesoporous materials;
  • Design and production of drug delivery systems based on mesoporous materials;
  • Surface chemistry and surface modification;
  • Use of mesoporous materials in dysbiosis and related diseases;
  • Drug-delivery systems based on natural and synthetic bioactive agents;
  • Characterization tools of surfaces and release behaviour.

Prof. Dr. Anton Ficai
Prof. Dr. Denisa Ficai
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


27 pages, 7766 KiB  
Metal–Organic Frameworks as Intelligent Drug Nanocarriers for Cancer Therapy
Pharmaceutics 2022, 14(12), 2641; - 29 Nov 2022
Cited by 6 | Viewed by 1789
Metal–organic frameworks (MOFs) are crystalline porous materials with periodic network structures formed by self–assembly of metal ions and organic ligands. Attributed to their tunable composition and pore size, ultrahigh surface area (1000–7000 m2/g) and pore volume (1.04–4.40 cm3/g), easy [...] Read more.
Metal–organic frameworks (MOFs) are crystalline porous materials with periodic network structures formed by self–assembly of metal ions and organic ligands. Attributed to their tunable composition and pore size, ultrahigh surface area (1000–7000 m2/g) and pore volume (1.04–4.40 cm3/g), easy surface modification, appropriate physiological stability, etc., MOFs have been widely used in biomedical applications in the last two decades, especially for the delivery of bioactive agents. In the initial stage, MOFs were widely used to load small molecule drugs with ultra–high doses. Whereafter, more recent work has focused on the load of biomacromolecules, such as nucleic acids and proteins. Over the past years, we have devoted extensive effort to investigate the function of MOF materials for bioactive agent delivery. MOFs can be used not only as an intelligent nanocarrier to deliver or protect bioactive agents but also as an activator for their release or activation in response to the different microenvironments. Altogether, this review details the current progress of MOF materials for bioactive agent delivery and looks into their future development. Full article
Show Figures

Figure 1

Back to TopTop